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The prognostic value of cancer stem cell markers in various cancer subtypes is a
well documented research area. Our findings show that the stem cell marker Lgr5 is
associated with an aggressive phenotype in neuroblastoma. Here, we discuss these
findings within the context of recent studies in several cancers such as lung, colorectal
and intestinal cancer, glioblastoma and ewing’s sarcoma. Neuroblastoma continues to
be an elusive disease, due to its heterogeneous presentation ranging from spontaneous
regression to aggressive metastatic disease and intertwined genetic variability. Currently,
the most significant prognostic marker of high risk disease and poor prognosis is
amplification of the MYCN oncogene, which is found in approximately 25% of cases
(Huang and Weiss, 2013). With this in mind, there is still much to learn about the
driving mechanisms of this aggressive pediatric tumor. Neuroblastoma development is
thought to be the result of aberrant differentiation of the cell of origin, embryonic neural
crest cells which then migrate and invade during the developmental stage (Joshi et al.,
2007). Aberrant cells are those which would, under normal conditions form the mature
tissues of the sympathetic ganglia and adrenal medulla. Tumors are known to develop
indiscriminately along the radius of the sympathetic ganglia, although it is well established
that the adrenal glands are fundamentally the most common primary site (Jessen and
Mirsky, 2005).
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CANCER STEM CELLS
Within recent years there has been an increased focus on cancer stem cells as important
drivers in both cancer relapse and in chemoresistance, thereby determining cancer aggressiveness.
Elucidation of themechanisms of how cancers stem cells arise in conjunction with the identification
of stem cell markers constitute fundamental steps in understanding oncogenesis, metastasis, and
resistance to therapy which are often observed in high risk neuroblastoma (Buhagiar and Ayers,
2015). Cancer stem cells, by definition, possess stem cell like characteristics including enhanced
self-renewal, migration, and chemo resistance.
Emerging evidence from several tumor types including neuroblastoma recognizes the potential
driving role of such cancer stem cells in disease progression, relapse and poor outcome
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(Kamijo and Nakagawara, 2012; Khalil et al., 2012; Kuo et al.,
2015). The existence of stem like characteristics in tumor cells
has been reported in high risk neuroblastomas, a sub-population
of cells which exhibit stem cell properties have been isolated
“Tumour Initiating Cells” which have the ability to initiate tumor
growth (Hansford et al., 2007). Recent data also suggests that
cancer stem cells may determine clinical behavior and treatment
response in neuroblastoma (Pandian et al., 2015; Ross et al.,
2015). Such studies pave the way for the analysis of genes
involved in neural crest development to evaluate whether their
deregulation in tumors is associated with progression and the
emergence of relapsed disease (Wurdak, 2012).
LGR5 AS A STEM CELL MARKER
In search of cancer stem cells markers, Barker and Clevers
in 2000 uncovered the dogmatic existence of adult stem cell
marker Lgr5 also known as G-protein coupled receptor (GPR49)
(chromosome 12; position 12q22–q23) (Haegebarth and Clevers,
2009). Structurally, Lgr5 is made up of 907 amino acids; it has
a large extracellular domain consisting of 17 leucine-rich repeats
and a seven-transmembrane domain (Carmon et al., 2012). Lgr5
transduces extracellular signals through its direct affect with
guanine nucleotide-binding (G) protein (Barker and Clevers,
2010). Lgr5 is specifically expressed on cancer stem cells (CSCs)
and is known to amplify the effect of Wnt/β-catenin signaling
by working as a receptor for R-spondins (RSPO), which are well
established and influential agonists of theWnt pathway (Carmon
et al., 2012), and known key drivers of oncogenesis (de Lau et al.,
2014).
THE ROLE OF LGR5 IN CANCER THE
STORY SO FAR
Lgr5 is a stem cell marker expressed during embryonic
development and in adult stem cells in the colon and kidney (Liu
et al., 2013). In recent years Lgr5 has been reported to promote
both growth and survival and is over expressed in several types of
cancer including colorectal cancers (van de Wetering et al., 2002;
Barker et al., 2007), where heightened expression was restricted
to actively proliferating cells, Ovarian cancer (McClanahan et al.,
2006), and Thyroid Cancer (Michelotti et al., 2015). Lgr5 is also
of relevance in pediatric tumors including glioblastomas (Nakata
et al., 2013) and Ewing’s Sarcoma (Scannell et al., 2013). Hermey
et al. (1999) also reported the presence of LGR5 in the murine
embryonic central nervous system, but not in adult tissue of the
same type, which may imply that Lgr5 expression is restricted to
neural crest precursors (Hermey et al., 1999).
CHARACTERIZATION OF LGR5 IN
NEUROBLASTOMA
To investigate this potential link between elevated LGR5
expression and aggressiveness in neuroblastoma we performed
Q-Real Time PCR to determine LGR5 mRNA expression in a
panel of 11 neuroblastoma cell lines displaying a wide range
of reported aggressiveness. Expression of LGR5 was quantified
using Taqman R© gene expression assay primers and probes (Life
Technologies, UK). Analysis was performed using the ABI Prism
7900 HT sequence detection system (Applied Biosystems, UK),
gene expression was quantified relative to GAPDH.
ELEVATED EXPRESSION OF LGR5 IN A
SUB-SET OF CELL LINES ESTABLISHED
AT RELAPSE AND ASSOCIATED WITH AN
AGGRESSIVE PHENOTYPE
Elevated LGR5mRNA expression was observed in three cell lines
BE2c, SKNAS, and SKNSH cell lines (p < 0.001) (Figure 1A).
High Lgr5 expression was observed in three cell lines (BE2c,
SKNSH, and SKNAS), all established from relapsed tumors.
Statistical analysis by One-way ANOVA revealed that there was
a significant correlation between cell line and expression of Lgr5
F(11,24) = 20.20, p < 0.0001. Dunnett’s post-hoc test revealed
a significant difference in the expression of Lgr5 in cell lines
SKSNH (p < 0.0001), SKNAS (p < 0.01), and BE2C (p < 0.05)
relative to SHEP cells. The SHEP cell line was established from
a primary tumor from patient it is a non-aggressive cell line
that isMYCN non-amplified and p53 wildtype (Carr et al., 2006;
Carr-Wilkinson et al., 2011).
To determine whether there was a correlation between Lgr5
and p53 mutational status cell lines were grouped into mutant
and wild type (Figure 1B). The two highest expressers of Lgr5
relative to GAPDH (BE2c and SKNAS) were also proven to be
p53mutant. Despite differences in the mean expression of LGR5
in p53 mutant and wild type cell lines no statistical significance
was observed (p = 0.487, Paired t-test). To look for a correlation
between cells harboring MYCN amplification, the cell lines were
then categorized by their status. Although differences in the
overall mean values were observed, no statistical correlation was
observed betweenMYCN amplification status and elevated LGR5
expression (p = 0.339, paired t-test; Figure 1C).
The differences in LGR5 expression were also confirmed at
a protein level using immunofluorescence on both NB69 and
BE2c cell lines (Figure 2). Two out three cell lines with increased
LGR5 expression, BE2C and SKNAS, are known to harbor a p53
mutation, (Carr et al., 2006; Ikegaki et al., 2014) and have been
reported to show aggressive chemoresistant behavior (Keshelava
et al., 2001; Tweddle et al., 2001).
LGR5 EXPRESSION AND
AGGRESSIVENESS IN NEUROBLASTOMA
To further investigate the potential role of LGR5 in
neuroblastoma publically accessible data bases were probed.
Recent microarray data deposited in the R2 Neuroblastoma
tumor database (http://r2.amc.nl) and (NCBI- Geo) show high
expression of LGR5 in MYCN amplified tumors compared with
non-amplified tumors (ANOVA p < 0.0001), high expression of
LGR5 was also associated with disease recurrence/progression
(ANOVA p = 0.0013) as well as stage 4 and 4s disease (ANOVA
p = 0.02). Stage 4 disease is characterized by metastatic
aggressive disease types whereas Stage 4s although metastatic
at diagnosis affects infant >18 months (http://r2.amc.nl).
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FIGURE 1 | Quantification of Lgr5 mRNA expression using quantitative
RT-PCR. (A) LGR5 mRNA expression in a panel of 11 neuroblastoma cell lines
established at diagnosis or relapse (N = 3). Elevated expression of LGR5 was
shown in BE2c, SKNAS and ****SKNSH (p < 0.0001), **SKNAS (p < 0.01) and
*BE2C (p < 0.05) (One-way ANOVA). Human foreskin fibroblasts were used as
a control cell line. (B) LGR5 mRNA expression in p53 mutant and wild-type
neuroblastoma cell lines (p = 0.487, Paired t-test). (C) LGR5 mRNA
expression in MYCN amplified and non-amplified sub groups. Cell lines were
divided into MYCN amplified (IMR32, BE2c, and LAN-1) and MYCN
non-amplified (p = 0.339, Paired t-test).
Microarray data from the mutated ALK driven neuroblastoma
mouse model showed an increase in LGR5 expression in
aggressive MYCN amplified tumors as well as aggressive tumors
with both MYCN amplification and mutated ALK which is in
agreement with the data presented in our study that LGR5 is
highly expressed in human cell lines derived from aggressive
relapsed cell lines (http://www.ncbi.nlm.nih.gov/geoprofiles/
101299025). This data further support the hypothesis that LGR5
may be a potential biological driver of disease progression and
relapse in neuroblastoma.
LGR5 EXPRESSION AS A MARKER OF
AGGRESSIVE DISEASE
Our study shows high LGR5 expression in SKNSH cells, which
have been reported to be highly chemoresistant (Blaheta et al.,
FIGURE 2 | Immunofluorescence staining of LGR5 in neuroblastoma
cell lines. (A) Immunofluorescence staining of Lgr5 in BE2c cells (B) Overlay
shows that it is primarily located in the cytoplasm of BE2c neuroblastoma cells
(C) NB69 cells show an absence of Lgr5 staining when stained under the
same conditions as the BE2c cell line, indicating low expression (D) Overlay
top right shows the morphology of the cell, with the absence of stain by phase
contrast microscopy.
2007). Given that SKNSH are reported to spontaneously switch
between S and N type cells (Ganeshan and Schor, 2014), further
investigation into how Lgr5 may play a potential role in this
spontaneous transition may lead to new insights into tumor
survival and proliferation.
Our findings are important and in agreement with Scannell
et al. (2013) who showed that Lgr5 levels were significantly raised
in cell lines derived from metastatic disease as well as in biopsies
taken from initial diagnosis, where patients quickly developed
untreatable disease. Their study showed that undifferentiated
neural crest stem cell expression of Lgr5 was substantially higher
than expression in cells differentiating into mesenchymal stem
cells (Scannell et al., 2013). A more recent study in glioblastoma
identified LGR5 as a marker of poor prognosis and a molecule
playing an instrumental role in the survival of brain cancer
stem-like cells; stem cell marker CD133+ sorted cells expressed
higher levels of LGR5 than the CD133 negative cell populations
and upon differentiation, LGR5 expression was significantly
repressed (Nakata et al., 2013). Upon further investigation it was
also noted that inhibiting expression at a genetic level resulted
in suppression of proliferation and cell death (Wang et al.,
2014).
It is conceivable that there is a link between Lgr5 expression
and maturation status of neural crest embryonic stem cells
and that high LGR5 expression is associated with more
aggressive phenotypes and increased relapse rate. Interestingly,
in neuroblastoma, Balamuth et al. (2010) identified increased
expression of Lgr5 (Gpr49) as a potential therapeutic target and
marker of disease in the murine TH-MYCN neuroblastoma
model and in human MYCN amplified neuroblastomas
(Balamuth et al., 2010).
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Taken together these studies indicate a potential role of LGR5
in neuroblastoma cancer stem cell development, warranting
further investigation into this protein in this disease.
Our findings support a growing body of evidence associating
LRG5 with aggressiveness in several cancer subtypes. Our
investigation shows high expression of LGR5 in the MYCN
amplified BE2C cell line, which previous studies reported
to be the most aggressive cell type in the panel of cells
under investigation (Keshelava et al., 2001; Tweddle et al.,
2001). Interestingly, the BE2C cell line is reported to comprise
exclusively of I type cells (Walton et al., 2004). Walton et al.
(2004) reported that cellular phenotype was an important
determinant of malignant potential in neuroblastoma and
identified a stem cell phenotype in I-type cells that was shown
to be 4–5 times more tumorigenic than N- and S-type cells. In
the same study immunocytochemistry of tumor sections from
patients with progressive disease exhibited higher numbers of
I-like cells than those biopsied from patients with progression-
free survival (Walton et al., 2004). More recently high expression
of stem cell related genes was shown in highly malignant I-
type neuroblastoma cells which could potentially imply that
these cells comprise specific sets of proteins which enable
sustained proliferation and enhanced survival (Ross et al.,
2015).
CONCLUSION AND FUTURE DIRECTIONS
In summary, we have shown elevated expression of LGR5 in
a subset of neuroblastoma cell lines which are derived from
patients at relapse and display an aggressive phenotype. These
data, in combination with available microarray data study, which
strongly support our findings, suggest a pressing need for further
investigation of the role of LGR5 and other stem cell markers
in tumor progression and as a prognostic biomarker in pediatric
tumors such as neuroblastoma, as well as other cancer sub-types.
Furthermore, these data imply that stem cell markers including
LGR5 may be a potential biomarker for aggressive disease
or important drivers of disease relapse and drug resistance.
Importantly, we demonstrate that this is an important area of
investigation and it is clear that a better understanding of the
role of stem cell related genes is required. Further understanding
would herald the potential for novel therapeutic intervention
to increase patient survival for childhood tumors, particularly
aggressive high risk neuroblastoma.
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